Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Four proteins (Scavenger receptor cysteine rich type 1 protein M130, Fatty acid binding protein 4, Plasminogen activator inhibitor 1 and Insulin-like growth factor-binding protein 2) with a previously established association with incident diabetes and 3 proteins (Cathepsin D, Galectin-4, Paraoxonase type 3) with a novel association with incident diabetes.
|
30670722 |
2019 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
However, inflammatory biomarkers hs-CRP [hazard ratio (HR) 1.16, (95% CI 1.05 to 1.29), p=0.005], procalcitonin [HR 1.34, (95% CI 1.07 to 1.69), p=0.012] and PAI-1 [HR 1.55, (95% CI 1.37 to 1.75), p<0.001] remained significantly associated with new-onset DM, even after multivariable adjustment for established predictors of DM.
|
29074040 |
2018 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
We recently revealed that plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor, is involved in diabetes, osteoporosis and muscle wasting induced by glucocorticoid (GC) treatment in mice.
|
28321652 |
2018 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
PAI-1 deficiency did not affect the mRNA levels of iNOS and IL-6 in F4/80- and CD11b-double-positive cells from the bone marrow of the damaged femurs decreased by diabetes in mice.
|
29534207 |
2018 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
|
9844142 |
1998 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The aim was to evaluate tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) concentration using enzyme linked immunosorbent assay method (ELISA) in diabetic foot syndrome (DFS) as compared to a group of healthy people and patients with diabetes mellitus without symptomatic vascular complications (DM2T).
|
28193577 |
2017 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
(1) The plasma PAI-1 levels of group A (60.39 ± 17.01 ng/L), group B (68.76 ± 17.81 ng/L) and group C and (68.63 ± 18.30 ng/L) are higher than that of controls (46.26 ± 26.04 ng/L); (2) Patients with genotype 4G/4G tended to exhibit higher PAI-1 level; (3) The distribution frequency of genotype 4G/4G in group C was significantly higher than in group A (42.4% vs. 28.7%, p < 0.05) and (4) In type 2 diabetic patients, the occurrence of diabetes nephropathy in genotype 4G/4G, 4G/5G and 5G/5G is 35.0%, 30.2% and 21.4%, respectively.
|
26616527 |
2016 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
The results indicate that there is no or minimal influence of the PAI-1 gene on either PAI-1 levels or the development of diabetic retinopathy in patients with diabetes mellitus.
|
7974340 |
1994 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Since TGF-beta1 is well known to stimulate the PAI-1 promoter, we suggest that TGF-beta1 and PAI-1 together constitute a positive feedback loop in the development of renal fibrosis in diabetes.
|
19786738 |
2009 |
Diabetes Mellitus
|
0.300 |
Therapeutic
|
group |
RGD |
Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats.
|
10910004 |
2000 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
The results of the present study suggest that LDL and VLDL from patients with DM reduce the generation of tPA and increase PAI-1 production through the activation of the PAI-1 promoter in vascular EC.
|
11788661 |
2002 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis.
|
12669679 |
2002 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Compared with 55 (33.3%) individuals in whom OSAS was not confirmed, OSAS patients had prolonged CLT (+12.8%), associated with higher PAI-1 antigen (+18.1%) (after adjustment for age, diabetes, and body mass index; both P < 0.01) and similar levels of TAFIa, plasmin, or antiplasmin.
|
27167858 |
2016 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM.
|
21519150 |
2011 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes.
|
15956119 |
2005 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
In a logistic regression analysis controlled for age, sex, BMI, and duration of diabetes, any retinopathy was significantly associated with fasting plasma glucose concentrations (P < 0.05), 2-h postload glucose (P = 0.02), and HbA1c (P = 0.008), but not with PAI-1 activity (P = 0.48).
|
9250459 |
1997 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
To address this, we used type 1 diabetes mouse model induced by streptozocin to be hyperglycemic for 8 weeks, and isolated endothelial cells that were used either freshly after isolation or after 2 to 3-week cell culture in normoglycemic conditions. mRNA expression profiling in diabetic mouse endothelial cells revealed significant and persistent up-regulation of Serpine1 encoding PAI-1, the hypo-fibrinolytic mediator leading to thrombotic diseases in diabetes, along with Rock2, Fn1 and Ccl2, whereas only Serpine 1 was persistently elevated in high glucose-treated mouse endothelial cells.
|
23454124 |
2013 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that a PAI-1 specific inhibitor alleviated diabetes-induced delays in skin and muscle repair.
|
29311999 |
2017 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase in cardiomyocytes and induction of TGF-beta and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells.
|
16339923 |
2006 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Compared to PBS treatment, APX3330 treatment significantly decreases plasminogen activator inhibitor type-1 (PAI-1), monocyte chemotactic protein-1 and matrix metalloproteinase 9 (MMP9) and receptor for advanced glycation endproducts expression in the ischemic brain of T1DM stroke rats.
|
29896433 |
2018 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin.
|
11887975 |
2001 |
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome.
|
18160587 |
2008 |
Diabetes Mellitus
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated.
|
24223897 |
2013 |
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1), produced partly from liver is a risk factor for macrovascular and microvascular complications of diabetes.
|
18700166 |
2008 |